Core Insights - Rapport Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing small molecule precision medicines for central nervous system disorders [1][6] - The company will present new data at the American Epilepsy Society Annual Meeting regarding the RNS® System and its correlation with seizure frequency reduction [2][3] Company Overview - Rapport Therapeutics specializes in precision medicines targeting CNS disorders, leveraging its RAP technology platform to create differentiated product candidates [6] - The lead product candidate, RAP-219, is a negative allosteric modulator designed to selectively target TARPγ8, which is expressed in specific brain regions [5][6] Clinical Trials and Research - A Phase 2a proof-of-concept trial for RAP-219 is underway, focusing on its efficacy as an anti-seizure treatment for drug-resistant focal epilepsy [2] - The trial aims to demonstrate a reduction in long episode frequency and clinically meaningful reduction in patient-reported seizures [2] Upcoming Presentations - Rapport will showcase multiple posters at the AES Annual Meeting, including studies on the antiseizure effects of TARPγ8 modulators and the pharmacokinetics of RAP-219 [3] - The presentations will cover the evolution of RAP-219 and its potential as a treatment for various CNS disorders [3]
Rapport Therapeutics to Present Data at American Epilepsy Society Annual Meeting